Stakeholders brace for first biosimilar application
Innovator companies and potential biosimilar applicants have expressed reservations about the new US scheme for biosimilar approval, which became law in March last year
Speakers on both sides of the debate discussed their concerns with the Biologics Price Competition and Innovation provision of President Obama’s landmark healthcare legislation during a session held at the BIO International Convention in Washington, DC on Monday.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.